Breaking News
Home / Business News (page 4)

Business News

Boehringer Ingelheim and University of Dundee Highlight Successful PROTAC Drug Discovery Program and Extend Their Ongoing Anti-Cancer Alliance

Ingelheim, Germany and Dundee, United Kingdom, 11 June, 2019 – Following the success of their ongoing alliance, Boehringer Ingelheim and the University of Dundee extend their collaboration to develop new medicines that target and destroy key cancer causing proteins. This brings together the expertise of Professor Alessio Ciulli, one of the …

Read More »

Genmab Signs Agreement with Janssen for Next-Generation CD38 Antibody, HexaBody-CD38

Copenhagen, Denmark; June 11, 2019 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today it has entered into an exclusive worldwide license and option agreement with Janssen Biotech, Inc. (Janssen) to develop and commercialize HexaBody-CD38, a next-generation human CD38 monoclonal antibody product incorporating Genmab’s proprietary HexaBody technology. Under the terms of the …

Read More »

Merck to Acquire Tilos Pharmaceuticals for up to $773 Million, Gaining Portfolio of Investigational Antibodies Modulating TGFβ

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it has entered into a definitive agreement to acquire Tilos Therapeutics, a privately held biopharmaceutical company developing therapeutics targeting the latent TGFβ complex for the treatment of cancer, fibrosis and autoimmune diseases. “At …

Read More »

Deciphera Expands Pipeline with Potential First-in-Class Autophagy Inhibitor to Treat Mutant RAS Cancers

WALTHAM, Mass.–(BUSINESS WIRE)–Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the addition of a new candidate to its pipeline, DCC-3116, a potential first-in-class small molecule designed to inhibit cancer autophagy, a key tumor survival mechanism. DCC-3116, discovered using the Company’s novel switch control inhibitor platform, is designed to inhibit autophagy by inhibiting …

Read More »

Janssen and nference Enter R&D Data Science Strategic Partnership that will Leverage nference’s AI Platform

CAMBRIDGE, Mass.–(BUSINESS WIRE)–nference, a leader in knowledge synthesis software solutions for the life sciences industry, today announced a multi-year alliance with Janssen Research & Development, LLC that will leverage the nference artificial intelligence (AI) platform to create a unified data science-powered connective fabric across the Janssen R&D organization. “We are …

Read More »

CStone and Bayer Partner to Evaluate PD-L1 Monoclonal Antibody CS1001 in Combination with Regorafenib

SUZHOU, China, June 9, 2019 /PRNewswire/ — CStone Pharmaceuticals (“CStone”; HKEX: 2616) today announced that the company has entered into a global clinical collaboration with China focus with Bayer HealthCare LLC to evaluate the safety, tolerability, pharmacokinetics (PK) and antitumor activity of its PD-L1 monoclonal antibody CS1001 in combination with …

Read More »

Taiho Oncology Enters Agreement with Otsuka to Commercialize Astex Pharmaceuticals’ Drug Candidates

PRINCETON, N.J., June 7, 2019 /PRNewswire/ — Taiho Oncology, Inc. announces that it has assumed commercialization responsibility from Otsuka Pharmaceuticals Co., Ltd., (Otsuka) for the novel fixed-dose combination of cedazuridine and decitabine (ASTX727) and guadecitabine (SGI-110) in the U.S. and Canada, subject to regulatory approvals. Taiho Pharma Canada, Inc., will …

Read More »

Biogen Completes Acquisition of Nightstar Therapeutics for Approximately $800 Million

CAMBRIDGE, Mass., June 07, 2019 (GLOBE NEWSWIRE) — Biogen (Nasdaq: BIIB) today announced that it has completed its acquisition of Nightstar Therapeutics (NST; Nasdaq: NITE), a clinical-stage gene therapy company, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders. As a result of the acquisition, Biogen now …

Read More »

Vertex Expands Collaboration with CRISPR Therapeutics and Acquires Exonics Therapeutics

BOSTON & WATERTOWN, Mass. & ZUG, Switzerland–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that the company is enhancing its gene editing capabilities to develop novel therapies for Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1) by expanding its collaboration with CRISPR Therapeutics and acquiring Exonics Therapeutics. Vertex …

Read More »

Bioventus to Co-Develop Next Generation Placental Tissue Product for Knee Osteoarthritis with MTF Biologics

DURHAM, N.C.–(BUSINESS WIRE)–Bioventus, a global leader in orthobiologic solutions, has entered into a development collaboration agreement with MTF Biologics, the world’s largest tissue bank, to co-develop a next generation placental tissue product for the treatment of painful musculoskeletal conditions, with an initial focus on knee osteoarthritis (OA). Terms of the agreement were …

Read More »